COMMUNIQUÉS West-GlobeNewswire

Transactions in Connection with Share Buy-back Program
16/06/2025
Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce [...]
Inquis Medical’s AVENTUS Thrombectomy System Receives FDA 510(k) Clearance for Treatment of Pulmonary Embolism
16/06/2025
Pioneering device combines precision clot removal with autologous blood reinfusion to address unmet needs in PE treatment MENLO PARK, Calif., June 16, 2025 (GLOBE NEWSWIRE) -- Inquis Medical , the leading innovator in [...]
BioAro Launches PanOmiQ™ Research in Breakthrough for AI-Driven Drug Discovery and Multi-Omics
16/06/2025
AI meets genomics in BioAro’s latest launch, unlocking faster, scalable drug discovery. PanOmiQ™ Research sets a new global benchmark for precision health innovation. BOSTON, June 16, 2025 (GLOBE NEWSWIRE) -- BIO [...]
FibroBiologics to Present at the BIO International Convention 2025
16/06/2025
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of [...]
Procès-verbal de l'Assemblée Générale Ordinaire d'IBA et résultats des votes
16/06/2025
Information réglementée Assemblée Générale Ordinaire du 11 juin 2025 Belgique, le 16 juin 2025 ( 17h50 ) – Ion Beam Applications SA (« IBA ») annonce que l’ensemble des résolutions proposées à ses actionnaires lors de l [...]
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
16/06/2025
NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares [...]
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
16/06/2025
—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile— —Patients report improved quality of life and daily functioning with ORLADEYO— [...]
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025
16/06/2025
BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced [...]
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
16/06/2025
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative [...]
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions
16/06/2025
– Hengrui to present six abstracts highlighting clinical progress of GLP-1/GIP dual receptor agonist HRS9531 (KAI-9531) and GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes and obesity – JIANGSU, China and [...]
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
16/06/2025
MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and [...]
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
16/06/2025
NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights Phase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the [...]
Aurora Spine Surpasses 1,500 Successful Surgeries Using DEXA-C™
16/06/2025
Award-Winning DEXA Technology™ Continues to Redefine Patient-Matched Spinal Care Please click to view image CARLSBAD, CALIFORNIA, June 16, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “ [...]
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.
16/06/2025
LOUISVILLE, Ky., June 16, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Nuvation Bio Inc. for IBTROZI™ (taletrectinib), a kinase [...]
Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology
16/06/2025
Trial represents first-ever CDC-sponsored clinical trial of vaccine delivered via “patch” technology and utilizes Micron’s first-in-class dissolvable microarray technology Research builds on Emory’s research on [...]
Transactions under Novonesis’ share buyback program
16/06/2025
Please read the announcement in PDF Attachment 2025_31_Trading_By_Management
FOXO TECHNOLOGIES INC. CREATES ACQUISITION VEHICLE AND APPOINTS NEW INTERIM CFO
16/06/2025
WEST PALM BEACH, FLORIDA, June 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“ FOXO ” or the “ Company ”) today announced that it formed a new, wholly-owned subsidiary intended to be used to [...]
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
16/06/2025
Capital Raised to Support Five Clinical Trials ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel [...]
Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
16/06/2025
MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete [...]

Pages